This Article Full Text Full Text (PDF) All Versions of this Article: 91/12/1198    most recent 01.RES.0000047506.52381.90v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kaye, D. M. Articles by Ahlers, B. A. Search for Related Content PubMed PubMed Citation Articles by Kaye, D. M. Articles by Ahlers, B. A. Related Collections Congestive

Reduced Myocardial and Systemic L-Arginine Uptake in Heart Failure

From Baker Heart Research Institute and Heart Centre, Alfred Hospital, Melbourne, Australia.

Correspondence to Dr David M. Kaye, Molecular Neurocardiology Laboratory, Baker Medical Research Institute, PO Box 6492, St Kilda Rd Central, Melbourne, Victoria 8008, Australia. E-mail david.kaye{at}baker.edu.au

Altered nitric oxide (NO) bioavailability has been ascribed an important role in the pathophysiology of congestive heart failure (CHF). In the peripheral vasculature, we recently demonstrated a depression of L-arginine transport in association with pharmacological evidence of reduced endothelial function. In contrast, increased myocardial NO generation has been proposed to account for a component of the reduced myocardial contractility in CHF, although this remains controversial. We determined the whole body clearance rate and cardiac fractional extraction of L-arginine during a steady-state intravenous infusion of [³H]L-arginine (300 nCi/min) in 9 healthy control subjects and 7 patients with moderate to severe CHF. In patients with CHF, there was a 30% reduction in the transcardiac extraction of [³H]L-arginine compared with controls (P<0.05), which was accompanied by a trend toward reduced [³H]L-citrulline release (P=0.06). In conjunction, the systemic clearance rate of [³H]L-arginine was significantly lower in patients with CHF (778±148 versus 1278±144 mL/min, P<0.05). In association with these biochemical indices, we observed a 38% reduction (P<0.05) in the mRNA expression of the cationic amino acid transporter CAT-1 in ventricular myocardial samples from patients with CHF compared with healthy unused donor myocardium, whereas myocardial NOS enzymatic activity and NOS protein were unchanged. These data indicate the presence of a significant reduction in the myocardial uptake of L-arginine in patients with CHF. Furthermore, this abnormality seems to be part of a systemic downregulation of L-arginine transport.

Key Words: heart failure • nitric oxide • amino acids • radioisotopes

This article has been cited by other articles:

				E. N. Dedkova and L. A. Blatter Characteristics and function of cardiac mitochondrial nitric oxide synthase J. Physiol., February 15, 2009; 587(4): 851 - 872. [Abstract] [Full Text] [PDF]

				C. V. Remillard and J. X.-J. Yuan Cardiac L-arginine transport: the CAT is back J. Physiol., May 1, 2007; 580(3): 699 - 700. [Full Text] [PDF]

				J. Steppan, S. Ryoo, K. H. Schuleri, C. Gregg, R. K. Hasan, A. R. White, L. J. Bugaj, M. Khan, L. Santhanam, D. Nyhan, et al. Arginase modulates myocardial contractility by a nitric oxide synthase 1-dependent mechanism PNAS, March 21, 2006; 103(12): 4759 - 4764. [Abstract] [Full Text] [PDF]

				S.E.S. Miner, A. Al-Hesayen, S. Kelly, T. Benson, J.J. Thiessen, V.R. Young, and J.D. Parker L-Arginine Transport in the Human Coronary and Peripheral Circulation Circulation, March 16, 2004; 109(10): 1278 - 1283. [Abstract] [Full Text] [PDF]

				J. P.F. Chin-Dusting, B. A. Ahlers, D. M. Kaye, J. J. Kelly, and J. A. Whitworth L-Arginine Transport in Humans With Cortisol-Induced Hypertension Hypertension, June 1, 2003; 41(6): 1336 - 1340. [Abstract] [Full Text] [PDF]